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Theprionprotein (PrPC)hasbeen suggested tooperate as a scaf-
fold/receptor protein in neurons, participating in both physiologi-
cal andpathological associated events. PrPC, laminin, andmetabo-
tropic glutamate receptor 5 (mGluR5) form a protein complex on
theplasmamembrane that can trigger signalingpathways involved
in neuronal differentiation. PrPC and mGluR5 are co-receptors
also for-amyloidoligomers (AOs)andhavebeenshowntomod-
ulate toxicity and neuronal death in Alzheimer’s disease. In the
present work, we addressed the potential crosstalk between these
two signaling pathways, laminin-PrPC-mGluR5 or AO-PrPC-
mGluR5, as well as their interplay. Herein, we demonstrated that
an existing complex containing PrPC-mGluR5 has an important
role inAObinding and activity in neurons. A peptidemimicking
the binding site of laminin onto PrPC (Ln-1) binds to PrPC and
induces intracellular Ca2 increase in neurons via the complex
PrPC-mGluR5. Ln-1 promotes internalization of PrPC and
mGluR5 and transiently decreases AO biding to neurons; how-
ever, thepeptidedoesnot impactAOtoxicity.GiventhatmGluR5
is critical for toxic signaling by AOs and in prion diseases, we
tested whether mGlur5 knock-out mice would be susceptible to
prion infection. Our results show mild, but significant, effects on
disease progression, without affecting survival of mice after infec-
tion. These results suggest that PrPC-mGluR5 form a functional
response unit by which multiple ligands can trigger signaling. We
propose that trafficking of PrPC-mGluR5maymodulate signaling
intensity by different PrPC ligands.
The prion protein (PrPC)3 was originally discovered as a sub-
strate for prion disease propagation in mammals (1). Several
studies on PrPC physiological function revealed dozens of PrPC
partners (2–4). In neurons, PrPC interactions with some of
these ligands trigger multiple effects, including regulation of
protein synthesis, differentiation, neuroprotection, and neuri-
togenesis (4–17). Given that PrPC is a glycosylphosphatidyl-
inositol (GPI)-anchored protein, signal transduction requires
the formation of complexes between PrPC and transmembrane
receptors. PrPC interactions have been demonstrated for 7
nicotinic acetylcholine receptor (5), group I metabotropic glu-
tamate receptors (10, 18, 19), ionotropic glutamate receptors
(20, 21) and purinergic receptors (22). These results suggest
that PrPC functions as an extracellular scaffolding protein, able
to organize multiprotein complexes at the cell surface (3, 4).
Increasing evidence indicates that such scaffolding can be neu-
rotoxic. For instance, when PrPC binds oligomeric forms of
-amyloid peptides (AO) (23), mal-adaptive signaling via
metabotropic glutamate receptor 5 (mGluR5) is elicited (18),
which initiates multiple changes in synaptic homeostasis, lead-
ing to excitotoxicity, endoplasmic reticulum stress, and even-
tually to synaptic degradation and neuronal cell death (18,
23–30). Thus, efforts have been made to disrupt this complex
and downstream pathways to prevent neurotoxic conse-
quences. Antibodies specific to certain PrPC regions were effi-
cient in preventing AO binding to the neuronal surface
(31–33), but such antibodies can also trigger toxic neuronal
signaling by themselves (34), mediated by PrPC N terminus
domain (35). The PrPC N-terminal domain, known as N1 pep-
tide, which is usually secreted into extracellular space by
-secretase action on PrPC, also exhibited a neuroprotective
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effect, presumably due to the sequestration of AOs from the
extracellular space (36, 37).
Stress-inducible phosphoprotein 1 (STI1), a secreted co-
chaperone that can bind and activate PrPC-dependent signal-
ing, has been shown to prevent the toxicity of AOs in cultured
neurons and brain slices (38). mGluR5 ligands (antagonists and
modulators) have also been shown to impact on AO toxicity
and cognitive deficits (18, 25, 29, 39, 40). The interaction
between laminin 1 chain and PrPC is of particular interest,
given that the PrPC-mediated signaling triggered by laminin 1
chain-mimicking peptide (1575–1584, Ln-1) depends on
mGluR5 (10). Of importance, Ln-1 signaling via the complex
PrPC-mGluR5 leads to neuritogenesis (10), a process known to
be disrupted by AO-induced toxicity (41, 42).
Here we investigated the relationship between Ln-1, PrPC,
and mGluR5 in AO toxicity and the role of mGluR5 in prion
infection. Our data suggest that a preformed complex contain-
ing mGluR5 and PrPC cooperates for A oligomer binding to
neurons, and that Ln-1 is ineffective to prevent AO-induced
toxicity. Moreover, mGluR5may also regulate some of the tox-
icity related to prion infection.
Results
Ln-1 Modulates AO Binding to Neurites—There is accu-
mulating evidence that PrPC binds AOs on the neuronal sur-
face, initiating toxic signaling pathways (18, 23, 27, 33, 38). Pre-
viously, we showed by multiple assays that a PrPC ligand, STI1,
decreases AO binding to the prion protein and prevents neu-
ronal death induced by AOs (38). Given that similarly to
AOs, Ln-1 also engages PrPC and mGluR5, we tested
whether the Ln-1-dependent activation of PrPC could affect
its binding to AOand toxicity.We observed a 30% decrease in
neurite-bound AOs when neuronal cultures were pretreated
with Ln-1 laminin peptide for 10 min (Fig. 1, A and B). Sur-
prisingly, there were no changes in AO binding when neuro-
nal cultureswere pretreatedwith Ln-1 peptide for 30min (Fig.
1,A andB). To further understand the potentialmechanisms by
which Ln-1 interferes with A biding to PrPC, we performed
an SPR study (Fig. 1C). Likely due to its small size, the Ln-1
peptide did not produce any signals on SPR (Fig. 1C), albeit each
preparation was able to cause PrPC-dependent calcium signal
in neurons, as described previously (10). Importantly, Ln-1
peptide was unable to interfere with AO binding (Fig. 1C).
These results suggest that treatment with Ln-1 peptide
decreases AO binding in live cells by a mechanism distinct
from competition with AO for PrPC binding sites.
Ln-1 Induces Decrease in Cell Surface PrPC—To investigate
the potential mechanisms by which Ln-1 peptide could mod-
ulate PrPC, we incubated neuronal CF10 cells (a PrPC-null cell
line) stably transfected with PrPC with Ln-1 peptide andmea-
sured cell surface PrPC by biotinylation. Treatment of cells with
Ln-1 for 10 min significantly decreased cell surface PrPC by
30–40%, which then returned to normal levels after 30 min of
Ln-1 treatment (Fig. 2A and B). This result was confirmed by
confocal and total internal reflection fluorescence imaging of
HEK293T cells transfected with PrPC fused to GFP, suggesting
that Ln-1 peptide treatment causes internalization of PrPC
(supplemental Experimental Procedures and Fig. S1). Ln-1
peptide triggers calcium signaling via PrPC-mGluR5 complex;
hence it is possible that the changes in cell surface PrPC levels
may reflect a desensitization mechanism. Treatment of PrPC-
CF10 cells with Ln-1 peptide led to a significant increase in
intracellular Ca2, but a second application of the peptide 10
min after the first treatment failed to elicit a second bout of
Ca2 signaling (Fig. 2, C and D). The same pattern of intracel-
lular Ca2 release was observed in neurons treated with Ln-1
peptide (Fig. 2, E and G). In contrast, when Ln-1 peptide was
reapplied 30min after the initial treatment, a robust increase in
intracellular Ca2was observed (Fig. 2, F andG). Thapsigargin
FIGURE 1. Ln-1 effect on AO binding to neurites and on-chip PrP. A, levels of the neurite-bound AOs decrease in cultures treated with Ln-1 peptide
(RNIAEIIKDI) for 10, but not for 30min. B, representative images of hippocampal neuronal cultures, immunostained for -amyloid (green) and tubulin (red), as
described under “Experimental Procedures.” Scale bar 10m.C, SPR kinetics of ligands binding to PrP on aNi-nitrilotriacetic acid chip. Ln-1 (green) or AOs
(red) were injected separately or simultaneously (orange). RU, response units.
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(1 M), a non-competitive inhibitor of the sarco/endoplasmic
reticulum Ca2ATPase (SERCA), which stimulates intracellu-
lar calcium mobilization, was used as a positive control (43).
These results suggest that about 30–40% of cell surface PrPC is
available for signaling by Ln-1 peptide, and when this pool of
PrPC is internalized, the remaining cell surface protein cannot
trigger calcium signaling.
We have shown previously thatmGluR5 antagonists blocked
the intracellular calcium signal induced by Ln-1/PrPC interac-
tion (10). To further test the role of these two proteins, we used
hippocampal cell cultures from mouse embryos lacking either
mGlur5 or PrPC or both. Ln-1 peptide-induced calcium
release is significantly decreased in mGluR5/ neurons (Fig.
2H). The residual signal probably depends on mGluR1, which
also was shown to be involved in Ln-1-PrPC pathway (10).
To investigate the relationship betweenmGluR5 and PrPC in
the Ln-1-induced PrPC internalization, we treated WT and
mGluR5/ neuronal cultures with Ln-1 or scrambled pep-
tide (Ln-SCR) and determined the amount of cell surface PrPC
andmGluR5 by immunofluorescence (Fig. 3,A–C) and cell sur-
face biotinylation (Fig. 3, D–I). Similar to CF10 cells, in WT
neurons, surface localization of PrPC decreased after treatment
with Ln-1 peptide for 10 min, but returned to its original level
30 min after the treatment, whereas the scrambled peptide had
no effect (Fig. 3,A,B,D, and F). In contrast, cell surface PrPC did
not respond to Ln-1 peptide treatment in mGluR5/ neu-
rons (Fig. 3, A, C, H, and I). Similarly to what was observed for
PrPC, in WT neurons, surface mGluR5 decreased after 10 min
of Ln-1 treatment and returned to its original levels after 30
min of treatment (Fig. 3, E and G). The scrambled peptide had
no effect onmGluR5 surface localization. These results suggest
that PrPC andmGluR5move together upon treatment with the
Ln-1 peptide. Moreover, the peptide induced internalization
of a fraction of cell surface PrPC (30%), which seems to depend
on the complex with mGluR5. It is possible that only the com-
plex PrPC-mGluR5 is able to respond to Ln-1 treatment. As a
control for the specificity for themGluR5 antibody,we detected
no mGluR5 signal in mGlur5/ protein extracts (supplemen-
tal Fig. S2).
PrPC and mGluR5 Cooperate to Transduce AO Signals—
The finding that 30% of the cell surface pool of PrPC is internal-
ized by Ln-1 peptides only in the presence ofmGluR5 led us to
further investigate how this complexmodulates the interaction
of AOwith neurons. Interestingly, although Ln-1 treatment
decreases AO binding to neuronal surfaces, possibly due to
PrPC internalization, this treatment was inefficient against
FIGURE 2. Effect of Ln-1 treatment on PrPC localization and intracellular calcium in cells. A and B, Ln-1 induces transient PrPC internalization in CF10
cells. A, representativeWestern blotting image of diglycosylated (D), monoglycosylated (M) and unglycosylated (U) forms of PrPC. B, quantification of surface/
total protein levels from at least 3 independent experiments. C and D, Ln-1 induces an increase in intracellular Ca2 levels in CF10 cells, and repeated
administration of Ln-1 over 10min has no effect. C, calcium response (relative Fluo-4 fluorescence kinetics) induced by Ln-1. Thapsigargin (1M) (THG) was
used as a positive control for intracellular calcium mobilization. D, quantification of Ca2 levels, averaged from at least 60 cells measured in at least 3
independent experiments. E–G, Ln-1 induces increase in intracellular Ca2 levels in primary hippocampal neurons. E, relative Fluo-4 fluorescence kinetics of
the initial Ln-1 treatment and the repeated one in 10 min. F, the same for the repeated 1 treatment in 30 min after the initial one. G, quantification of Ca2
levels, averaged from at least 60 cells measured in at least 3 independent experiments. H and I, Ln-1-induced increase in intracellular Ca2 in wild-type and
mGluR5/ neurons. H, relative Fluo-4 fluorescence kinetics. I, quantification of Ca2 signal amplitude, averaged from at least 60 cells measured in at least 3
independent experiments. Error bars indicate mean S.E. *, p 0.05; ***, p 0.001.
Role of PrPC-mGluR5 Complex in Alzheimer’s Disease
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AO-induced neuronal death (Fig. 4,A and B). This result sug-
gests that indeed Ln-1 peptide cannot compete effectively
withAOs to prevent toxicity.We then investigated the impact
of PrPC-mGluR5 complex in AO interaction with neurons.
The interaction of AOwith neuronal cell surface was reduced
by40% in the absence of PrPC ormGluR5 (Fig. 4,C andD). In
contrast, in neuronal cultures from double knock-out mice
lacking both PrPC and mGluR5, AO binding to neurites was
reduced by 58% (Fig. 4, C and D). Of note, previous findings in
COS-7 cells, overexpressing PrPC and/or mGluR5, suggested
that PrPC, but not mGluR5, is needed for AO binding to the
cell surface (18). However, Renner et al. (39) have shown, sim-
ilar to the present results, that A binding is decreased in
mGluR5-null neurons. To confirm the PrPC dependence on the
effect of Ln-1, we performed the same experiments described
above in PrP/ neurons and in CF10 cells. In both cases, in the
absence of PrPC, pretreatment with Ln-1 peptide did not alter
AO binding to either PrP/ neurons or CF10 cells (supple-
mental Fig. S3). To further explore the role of PrPC-mGluR5
complex in the toxic effects of AO, we investigated Ca2 sig-
naling (Fig. 4,E and F).We confirmed previous results fromUm
et al. (18) that the absence of PrPC almost abolished Ca2 sig-
naling induced by AOs. In contrast, some residual Ca2 sig-
naling was still triggered in the absence of mGluR5 (Fig. 4, E
and F). Interestingly, in double-knock-out neurons, lacking
both PrPC and mGluR5, Ca2 signaling was abolished, a sim-
FIGURE 3. Ln-1-induced transient internalization of PrPC and mGluR5 in primary neurons. A–C, WT (A and B) and mGluR5/ (A and C) hippocampal
neuronal cultures were treated with Ln-1 for 10 or 30 min, or with Ln-SCR (Ln-1 scrambled peptide: IRADIEIKID), and the neuronal cell surface was
immunostained with 8H4 antibody. Quantification of surface PrPC was done for eight random fields of view for each condition (A). Primary neuronal cultures
were prepared from at least five embryos of each genotype. arb units, arbitrary units. B and C, representative images of WT (B) and mGluR5/ (C) cultures,
corresponding to each treatment. Scale bar 20 m. D–I, primary cortical neurons were treated with Ln-1 for 10 or 30 min, or with Ln-SCR, after which the
surface proteins were biotinylated. Levels of surface PrPC (D and F) andmGluR5 (monomer dimer, E andG) inWT cultures, and of surface PrPC inmGluR5/
cultures (H and I), were quantified as the ratio of biotinylated protein to the total protein levels on Western blot (D, E, and H), and then compared using
GraphPad 5.0 software (F, G, and I). con, control. Error bars indicate mean S.E. *, p 0.05.
Role of PrPC-mGluR5 Complex in Alzheimer’s Disease
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ilar result as observed for neurons lacking only PrPC (Fig. 4,
E and F).
Prion Disease Onset Is Delayed in mGluR5/Mice—Previ-
ous studies suggest that various misfolded proteins, including
PrPSc, can interact with and corrupt the signaling mediated by
PrPC, similar to AOs (44). However, it is unknown whether
the PrPC-mGluR5 complex has a role in other protein misfold-
ing diseases. This might be particularly important in prion dis-
eases, in which PrPSc toxicity could impact mGluR5 signaling.
Therefore, we infected wild-type and mGluR5/ mice with
prions (prion strain RML (named for Rocky Mountain Labora-
tories)) and followed the mice after infection. Interestingly,
there was a significant delay in disease onset, determined by
observing clinical symptoms, in mice lacking mGluR5 when
compared with control mice (Fig. 5A). This, however, did not
affect mouse survival (Fig. 5B). Biochemical evaluation of pro-
tease-resistant PrPSc and total levels of PrPC showed no differ-
ence between genotypes (Fig. 5,C andD). These results suggest
that pharmacological targeting mGluR5 may delay some prion
disease symptoms, but it is unlikely to extend the life of prion
disease-affected individuals.
Discussion
In this work, we explored the ensemble PrPC-mGluR5 and its
potential ligands Ln-1 and AOs on the pathological mecha-
nisms involved in neurodegeneration. Our results suggest that
Ln-1 signals via a small portion of cell surface prion protein.
This conclusion is based on the fact that after treatment with a
peptide mimicking the effects of Ln-1 chain, a transient
decrease of 30% in cell surface PrPC was observed. This minor
decrease of cell surface PrPC prevented subsequent signal by
the Ln-1 peptide, suggesting that the majority of PrPC at the
membrane is not available for Ln-1-induced Ca2 increase.
Although the mechanisms involved in this limited signaling by
PrPC-mGluR5 are currently unclear, it is possible that Ln-1
peptide may not be able to induce the association of PrPC with
mGluR5, but rather it only activates the complex if it is already
formed.
FIGURE 4. Effect of PrPC andmGluR5 absence and of Ln-1 treatment onAO toxicity hallmarks. A and B, the effect of pretreatment of neuronal cultures
with Ln-1 or Ln-SCR (scr) on AO-induced cell death. Cell death was registered for cultures prepared from at least five embryos for each condition (A).
Representative images show live (green) and dead (red) cells (B). Scale bar 100m. C andD, AObinding to neurites lacking PrPC, mGluR5, or both proteins.
Representative images showing immunostaining of AOs (red) and tubulin (green) (C). Levels of bound AOs were normalized to neurite area (calculated by
tubulin immunostaining) from eight random fields of view of neuronal cultures prepared from at least five embryos for each genotype (D). Scale bar 20m.
E and F, AO-induced increase in intracellular Ca2 in neuron lacking PrPC (red), mGluR5 (blue), or both proteins (purple). E, calcium response (relative to
baseline Fluo-4 fluorescence, F1/F0) kinetics in the neurons treated with 500 nM AOs. F, quantification of the peak signal from E. Data were collected from at
least 20 cells in at least 3 independent experiments for each genotype. Statistical comparison was done with one-way analysis of variance followed by Tukey
post hoc test. Error bars indicate mean S.E. For a and b, p 0.05; for a and c, p 0.001.
Role of PrPC-mGluR5 Complex in Alzheimer’s Disease
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Evidence that PrPC can be found in a complex with mGluR5
andmGluR1 without any stimulation is abundant.We (10) and
others (18, 19, 25) found that PrPC and mGluRs can associate
biochemically. We have also reported a functional association
between PrPC and mGluR5 in non-neuronal cells for Ln-1
peptide signaling (10), whereas others have shown similar func-
tional association for AOs (18, 25). In the current work, we
confirmed and extended these results, in primary neuronal cul-
ture from embryos lacking either PrPC or mGluR5 or both,
showing that a complex formed between PrPC and mGluR5 is
important for AO interaction with neurons. AO binding to
neurons seems to be partially affected by the lack of PrPC and in
the same proportion by the lack of mGluR5. These results are
consistent with previous observations that both mGluR5 (10,
18, 25, 39) and PrPC (21, 23, 27, 33, 38) can function as receptors
for extracellular ligands, including AOs and Ln-1. Interest-
ingly, in neurons lacking both mGluR5 and PrPC, the decrease
in AObinding was not additive. Previous experiments in neu-
rons showed that in mGluR5 neurons, binding of AOs is
decreased (39), whereas experiments in COS7 cells overex-
pressing mGluR5 suggests that AOs cannot bind directly to
mGluR5 (18). Overall, our study suggests that although AO
may be able to interact with either PrPC or mGluR5 indepen-
dently, as proposed previously (23, 39, 45), a proportion of olig-
omers may also bind to a preformed complex. These results are
consistent with the notion that a certain proportion of PrPC
may already be in a functional complex withmGluR5 at the cell
surface.
Trafficking of the GPI-anchored PrPC has been extensively
studied (46–53). Although most GPI-anchored proteins are
thought to be internalized via a non-clathrin-mediated mecha-
nism (54), multiple data suggest that PrPC is internalized in
dynamin-sensitive vesicles (48) by clathrin-mediated endocy-
tosis (52, 55–58). Constitutive internalization of cell surface
PrPC seems to depend on LRP1, a scaffold protein that connects
PrPC to clathrin-coated vesicles (59, 60). Here we described a
novelmechanismbywhich Ln-1 peptide induces a decrease in
only a fraction of cell surface PrPC, and it can also decrease the
same proportion of cell surface mGluR5. Interestingly, the
absence of mGluR5 impairs Ln-1 peptide-induced internal-
ization of PrPC, suggesting that the complex PrPC-mGluR5may
internalize together. mGluR5 can be internalized in a constitu-
tive or an agonist-induced way. Constitutive internalization
was found to proceed in a clathrin-independent (61) but rather
in a GRK2- (62) and caveolin-1/lipid raft-dependent (63)
manner. The mechanisms of agonist-induced endocytosis of
mGluR5, which are important for controlling NMDA plasticity
in the hippocampus (64), and, possibly, for the roles of mGluR5
in neuropsychiatric disorders (65, 66), are not completely clear.
Although PrPC and mGluR5 have not yet been shown to be
present in intracellular vesicles together, both proteins can be
found in the post-synaptic density. Moreover, PrPC co-immu-
noprecipitates not only with mGluR5 (10, 18), but also with
mGluR5 intracellular mediators, including Homer 1b (19),
shown previously to regulate mGluR5 trafficking (67). It is pos-
sible, therefore, that at least a portion of the PrPC-mGluR5
complex is internalized together, which could have important
implications in mGluR5 functions in healthy organisms and in
disease. Of note, AO treatment of cells can trap both mGluR5
(18) and PrPC (68) at the cell surface, suggesting that part of the
AO-induced toxic signaling may occur due to the longer per-
manence of complexes formed between mGluR5 and PrPC at
the cell surface.
It has been suggested that signaling by PrPC and mGluR5
may be corrupted by AOs, leading to abnormal activation of
Fyn kinase and neurotoxicity (18). Why do different ligands,
such as AO and Ln-1, which use similar signaling pathways,
have distinct effects? Ln-1 interaction with PrPC triggers neu-
ritogenesis, whereas AOs cause neurotoxic effects. One pos-
sibility is that the ability of these two ligands to trigger internal-
FIGURE 5. Prion infection in WT andmGluR5/mice. A, disease onset in infected mice was determined as described under “Experimental Procedures.” B,
mouse survival upon prion infection. C, Western blotting of PrPC in non-infected WT and mGluR5/mice. D, Western blotting of PrPSc in infected WT and
mGluR5/mice as determined by proteinase K cleavage assay. Four mouse brains were used for each condition for Western blotting analyses. Data were
analyzed and compared by Mantel-Cox log-rank test. A, p 0.0018, and B, p 0.3215.
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ization or increased permanence of the PrPC-mGluR5 complex
at the membrane could regulate subsequent signaling in neu-
rons. Interestingly, ligands that can trigger internalization of
PrPC, such as Ln-1 (present results) or STI1 (46), are usually
not toxic and can trigger survival signaling. A second possibility
is that Ln-1 or its peptide cannot activate the formation of
PrPC-mGluR5 complex, whereas AOs can (25). These results
are consistent with the hypothesis that PrPC is an extracellular
scaffolding protein able to seed the formation of several multi-
protein complexes that underlie neuronal signaling (3). Biasing
the interaction of PrPC with other receptors, such as 7 nico-
tinic acetylcholine receptors (5, 38, 69), may be also an effective
way to diminish toxic effects of AOs.
Despite a critical role for PrPC and mGluR5 in Alzheimer’s
disease, it seems that for toxicity, due to PrPSc buildup, lack of
mGluR5 is not critical. Although drugs that interfere with
mGluR5 and genetic elimination of mGluR5 seem to improve
the outcomes in mouse models of Alzheimer’s disease (19, 70),
we observed only marginal improvements in clinical signs dur-
ing prion infection. Our data suggest a small, but unlikely, life-
extending benefit, by inhibiting the activity of mGluR5 in prion
diseases. It is possible that other mechanisms triggered by the
accumulation of PrPSc, such as endoplasmic reticulum stress
(17), which has recently been shown to play a major role in
prion and Alzheimer’s diseases (71–73), need to be targeted
simultaneously with mGluR5 for potential therapeutic benefits
in these neurodegenerative diseases.
In summary, we find that Ln-1 peptide, which signals via
PrPC-mGluR5, does not affect AO-mediated neurotoxicity.
However, our experiments suggest the possible existence of the
complex PrPC-mGluR5 at the cell surface even in the absence of
any ligands. Further experiments are required to determine by
which extent the complex PrPC-mGluR5 can regulate each
other’s traffic and function in distinct physiological and patho-
logical settings. mGluR5 has been proposed as a target in sev-
eral psychiatric and developmental conditions, including frag-
ile X syndrome, schizophrenia, and autism spectrum disorders
(74–77). It will be important to delineate whether its complex
with PrPC also plays a role in these diseases. Our results support
the notion that mGluR5 function is coupled to PrPC and that
targeting this complex might be beneficial in neurodegenera-
tive diseases.
Experimental Procedures
Animals—Prnp/ mice in a C57BL/6 background were
kindly donated by Dr. Frank Jirik, University of Calgary (78).
mGluR5/ (Grm5tm1Rod/J) mice in a C57BL/6 background
were purchased fromThe JacksonLaboratory (BarHarbor,ME,
stock number 003558) (79). Procedures were conducted in
accordance with approved animal use protocols at the Univer-
sity of Western Ontario (2008/127), University of British
Columbia (A11-0138), and the A. C. Camargo Cancer Center
(037/09) following Canadian Council of Animal Care (CCAC)
and National Institutes of Health guidelines.
Peptide Preparations—AOs were prepared from A(1–42)
peptide (rPeptide) as described previously (38). Briefly, the pep-
tide was monomerized in hexafluoroisopropanol, dried in a
SpeedVac centrifuge, restored in DMSO to 1 mM solution, and
diluted in PBS (for intracellular calcium experiments) or F-12
medium (Invitrogen) (for the neuronal survival experiments) to
a final concentration of 100 M (hereafter monomer concen-
tration used as AO concentration). After incubation for 24 h
at 4 °C, AOswere used immediately or stored at80 °C for no
more than 4 weeks. Peptide preparation quality was checked by
Western blotting with 6E10 (1:2000, Covance) antibody, and
similar preparations were fully characterized using size exclu-
sion chromatography aswell as by atomic forcemicroscopy (28,
38). Ln-1 (RNIAEIIKDI) or Ln-SCR (IRADIEIKID) peptides
were synthesized by GenScript and dissolved in PBS to the final
concentration of 1mM and then used immediately or stored for
not more than 2 weeks at20 °C.
Primary Neuronal Cultures—Mouse primary cortical and
hippocampal neuronal cultures were prepared from embryonic
day 17 embryos as described previously (10, 38). Briefly, corti-
ces and hippocampi were separated from embryonic brains,
dissociated in Hanks’ balanced salt solution (Invitrogen), and
trypsinized (0.25%) for 20 min at 37 °C). Neurons were plated
onto dishes coated with 5 g/ml poly-L-lysine (Sigma) in min-
imum essential medium Eagle (Invitrogen) containing 10% FBS
(Invitrogen) and antibiotics (100 g/ml streptomycin, 100
units/ml penicillin). Four hours after plating, the medium was
replaced with the Neurobasal medium (Invitrogen), supple-
mented with B-27 (Invitrogen), glutamine (0.5 mM) (Invitro-
gen), penicillin (100 units/ml), streptomycin (100 g/ml), and
glucose (0.25%).
Calcium Imaging—Mouse primary hippocampal neurons
were plated onto poly-L-lysine-coated 35-mm glass-bottom
dishes (MatTek, Ashland,MA) at7.5 104 cells/dish density.
On day 14, cultures were washed with Krebs-Ringer buffer
(KRH) (124 mM NaCl, 4 mM KCl, 25 mM HEPES, 1.2 mM
MgSO4, and 10mM glucose), and loaded with 5M of the intra-
cellular Ca2 indicator Fluo-4-AM (Invitrogen), diluted in
KRH buffer with 2 mM CaCl2, for 1 h at 37 °C. The cells were
washed three times with KRH with (for AO experiments) or
without calcium (Ln-1 experiments). Data acquisition was
performed in a LSMMeta 510 confocal microscope, with exci-
tation at 488 nm (argon laser), and emission was collected with
a 505–530-nm band-pass filter. The fluorescence was normal-
ized as F1/F0 (F1, maximal fluorescence after the treatment; F0,
basal fluorescence before the treatment). Imaging analysis was
performed using ImageJ software (WCIF ImageJ, National
Institutes of Health). Experiments were carried out with 3
different dishes, and 20–30 cells were monitored in each
experiment.
CF10 Cell Culture and Ca2 Imaging—CF10, a PrPC-null
immortalized cell line, and its counterpart expressing 3F4-
tagged mouse PrPC were obtained as described previously (46).
CF10 cells were plated onto 35-mm glass-bottom dishes (Mat-
Tek) (104 cells), and then serum-starved for 48 h with medium
change after 24 h. Cells were loaded with Fluo-4-AM (5 M/30
min) and thenwashed three timeswithKRHbuffer. Data acqui-
sition was performed in a confocal Bio-Rad Radiance 2100/
Nikon TE2000U microscope, with excitation at 488 nm (argon
laser), and emission was collected with a 522–535-nm band-
pass filter as described previously (10).
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CF10 Cell Surface Protein Biotinylation and Western
Blotting—Biotinylation of cell surface proteins was performed
as described (46, 80). Briefly, cells were incubated with Ln-1
(120 M) for 10 or 30 min and then transferred to ice, washed,
and incubated on ice in PBS/CM (PBS supplemented with 1.0
mM MgCl2, 0.1 mM CaCl2). Cell surface proteins were biotiny-
lated with sulfo-NHS-SS-biotin (Pierce) for 40 min on ice. To
quench the biotinylation reaction, cells were washed and incu-
bated for 30minwith cold 100mMglycine in PBS/CM, followed
by three washes with cold PBS/CM, and then proteins were
extracted using 100mMTris-HCl, 150mMNaCl, 10mM EDTA,
0.5% Triton X-100, 0.5% deoxycholic acid, pH 7.4. Biotinylated
proteins were separated from non-biotinylated proteins by
pulldown of NeutrAvidin beads from equivalent amounts of
total cellular protein (800 g) from each sample. The biotiny-
lated proteins were subjected to SDS-PAGE, followed by elec-
troblotting onto PVDF membrane, and then revealed using a
mouse anti-PrPC antibody as described previously (81). For
quantification, the major glycosylated band of PrPC in non-
saturated blots was analyzed using ImageQuant TL and nor-
malized by the expression of PrPC in the lysates.
Neuronal cell Surface Protein Biotinylation and Western
Blotting—Mouse primary cortical neuronswere plated on poly-
lysine-coated 60-mm Petri dishes at 3  106 cells/dish den-
sity. On day 8, cultures were treated with Ln-1 or Ln-SCR for
a specific amount of time after which the cells where washed
with ice-cold PBS and the cell surfacewas biotinylated using the
cell surface protein isolation kit (catalogue number 21328,
Thermo Scientific) as described in the supplier’s manual. In
short, cells were incubated with NHS-SS-biotin reagent for 1 h,
washed, and lysed. Biotinylated protein was collected from the
lysate by incubationwithNeutrAvidin agarose, followed by elu-
tion with 50 mM dithiothreitol. Untreated lysate was used for
total protein quantification. PrPC andmGluR5 in cell surface or
total cellular fractions were quantified by Western blotting
using 8H4 (1:2500, Abcam ab61409, Lot: GR82819-6) and anti-
mGluR5 (1:1000, Millipore AB5675, Lot: 2279534) antibodies,
respectively.
Peptide Binding and Protein Internalization Imaging—For
AO binding and PrPC internalization experiments, primary
neuronal cultures were plated on glass coverslips at 5  104
cells/dish density. On day 15, cultures were washed with KRH
buffer and treated with 250 nMAO solution in KRH buffer for
15 min or with 40 M Ln-1 or Ln-SCR solution for 10 or 30
min. After that, cover glasses were washed with ice-cold PBS,
permeabilized for 5 min in PBS containing 0.5% Triton X-100,
and fixed with 4% paraformaldehyde for 20 min. For immuno-
fluorescence, cover glasses were incubated with 6E10 (for AO
binding, 1:350, Covance, catalogue number SIG-39300, lot
number D13EF01399) or 8H4 (for PrPC internalization, 1:350)
and anti-tubulin (1:300, Abcam) antibodies overnight at 4 °C,
followed by Alexa Fluor 633 anti-mouse IgG and Alexa Fluor
488 anti-rabbit IgG (1:1000, Invitrogen) for 1 h at room tem-
perature. After that, cover glasses weremounted on slides using
Immu-mount (Thermo Fisher Scientific) and imaged with an
LSM 510 Meta ConfoCor microscope. Integrated fluorescence
intensity was normalized by total neurite area calculated from
tubulin fluorescence, and then for each treatment normalized
toward the wild-type or non-treated controls.
Surface Plasmon Resonance—SPR was measured using a Bia-
core X system (GE Healthcare Life Sciences) equipped with a
nitrilotriacetic acid sensor chip as described previously (38).
Briefly, the chip was nickel-charged and uniformly covered
with His6-tagged PrP to the final SPR signal of 10,000
response units. Ln-1, AO, and their mix were diluted in 25
mM HEPES, 150 mM NaCl, 10 mM imidazole, pH 7.0, and
injected at 5 l/min. On-kinetics were registered for 6 min,
followed by off-kinetics registered for 2 min. The chip surface
was regenerated between injections by a short injection of 10
mM HCl. SPR curves for binding to PrP were analyzed by max-
imum signal comparison.
LIVE/DEAD Cell Viability Assay—Mouse primary hip-
pocampal neurons were plated onto poly-L-lysine-coated
4-well dishes and cultured for 10 days. On day 11, AOs (1M)
were added to cultures. Some cultures were pretreated with
Ln-1 or Ln-SCR peptides (40 M) for 10 or 30 min. Following
48-h treatment, cultures were analyzed with a LIVE/DEAD cell
viability assay (Invitrogen) according to the manufacturer’s
manual. Live and dead cells were counted from fluorescence
images taken with Zeiss LSM 510 Meta confocal microscope
equipped with 10/0.3 objective lens, and the cell death rate
was calculated as the percentage of dead cells in the total
amount of cells.
Prion Infection andWesternBlotting—For prion infection the
mice were anesthetized with isoflurane. The injection was
made through the skull into the brain with a 26-gauge needle
attached to a syringe containing the prion material (5% RML
strain). The total volume injected per mouse was 20l. Follow-
ing the injection, the mice were allowed to recover from the
anesthesia in their home cage. Early signs of mouse prion dis-
ease were evaluated including ataxia (lack of coordination) and
extension of the hind limbs when mice are hung by their tails.
As the disease progressed, affected mice showed hypokinesia,
waddling gait, difficulty righting from a supine position, weight
loss, and deficient grooming. When held by their tails, some
affected mice assume an unusual flexed posture, with all four
limbs clasped together. For the onset of the disease, the follow-
ing parameters were analyzed: 1) foot clasp reflex when picked
up by the tail and 2) observation of kyphosis while the mouse
was in the cage. These clinical observations were done on a
weekly basis prior to onset and daily upon onset of disease.
Experimental end point was reached once a mouse no longer
could right itself within 30 s. The incubation period when
injecting 20 l of 5% RML strain intracranially is 120 days.
Once the mice reached the experimental end point (described
above), they were euthanized by inhalation of CO2 and their
brains were harvested and frozen on dry ice.
For prion scrapie analyses, brain homogenate in PBS (250g
of total protein)was digestedwith 50g/ml proteinaseK for 1 h
at 37 °C, and then samples were boiled in SDS loading buffer
and separated with 14% SDS-PAGE. After electrotransfer to a
PVDF membrane (Immobilon, Millipore) protein bands were
probed with SHA31 antibody (1:30000, Spibio Inc., catalogue
number A03263, lot number 0107).
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Statistics—Western blots and immunocytochemistry data
were quantified using the ImageJ software (National Institutes
of Health, Bethesda, MD) and statistically analyzed using one-
way analysis of variance with Tukey’s post hoc or by Student’s t
test using Prism software (GraphPad, La Jolla, CA). For prion
disease onset and progression, data were analyzed and com-
pared by Mantel-Cox log-rank test.
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